Irene
Manrique Sáenz de Tejada
Profesional Investigadora
Argitalpenak (12) Irene Manrique Sáenz de Tejada argitalpenak
2023
-
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
Blood, Vol. 141, Núm. 6, pp. 579-591
-
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Blood cancer discovery, Vol. 4, Núm. 5, pp. 365-373
2022
-
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
Blood Advances, Vol. 6, Núm. 2, pp. 690-703
2021
2020
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
2019
-
The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma
Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187
2015
-
Co-migration of colon cancer cells and CAFs induced by TGFβ1 enhances liver metastasis
Cell and Tissue Research, Vol. 359, Núm. 3, pp. 829-839
-
Febrile young infants with altered urinalysis at low risk for invasive bacterial infection. A Spanish pediatric emergency research network's study
Pediatric Infectious Disease Journal, Vol. 34, Núm. 1, pp. 17-21
-
Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells
Prostate, Vol. 75, Núm. 11, pp. 1137-1149
-
The inhibitor of differentiation isoform Id1b, generated by alternative splicing, maintains cell quiescence and confers self-renewal and cancer stem cell-like properties
Cancer Letters, Vol. 356, Núm. 2, pp. 899-909
2014
-
Id-1B, an alternatively spliced isoform of the inhibitor of differentiation-1, impairs cancer cell malignancy through inhibition of proliferation and angiogenesis
Current Molecular Medicine, Vol. 14, Núm. 1, pp. 151-162